Blood pressure variability (BPV) is an age-related hemodynamic risk factor for neurodegeneration, but it remains unclear whether distinct forms of BPV display independent or interactive effects on brain health.
Objective
Investigate whether high beat-to-beat BPV, when combined with increased pulse pressure variability, a form of BPV associated with arterial stiffness, exacerbates markers of neurodegeneration.
Methods
Older adults (N = 105) without major neurological or systemic disease were recruited for brain magnetic resonance imaging and continuous blood pressure (BP) monitoring to quantify beat-to-beat BPV through systolic average real variability (ARV) and pulse pressure variability using arterial stiffness index (ASI). The interactive effect of ARV and ASI on medial temporal lobe atrophy, plasma neurofilament light chain (NfL), and plasma glial fibrillary acidic protein (GFAP) was studied using hierarchical linear regression in older adults. Voxel-based morphometry was used to confirm region-of-interest analysis findings.
Results
The interaction between higher ARV and higher ASI was significantly associated with left-sided medial temporal lobe atrophy in both the region-of-interest (left hippocampus β = −252.79, p = 0.0002, right hippocampus β = −193.56, p = 0.001, left entorhinal cortex β = −0.13, p = 0.007), and false discovery rate-corrected voxel-based morphometry analysis (p = 0.03). The interactive effect was also significantly associated with increased plasma NfL (β = 3.88, p = 0.01), but not GFAP.
Conclusions
The interaction between ARV and ASI is independently associated with neurodegenerative markers, including medial temporal lobe atrophy and plasma NfL, in older adults. These findings suggest that greater hemodynamic instability is associated with increased risk for neurodegenerative processes.
HeshmatollahAMaYFaniL, et al.Visit-to-visit blood pressure variability and the risk of stroke in The Netherlands: a population-based cohort study. PLoS Med2022; 19: e1003942.
2.
MaYSongAViswanathanA, et al.Blood pressure variability and cerebral small vessel disease. Stroke2020; 51: 82–89.
3.
SibleIJBangenKJBlankenAE, et al.Antemortem visit-to-visit blood pressure variability predicts cerebrovascular lesion burden in autopsy-confirmed Alzheimer's disease. J Alzheimers Dis2021; 83: 65–75.
4.
LohmanTSibleIKapoorA, et al.Blood pressure variability, central autonomic network dysfunction, and cerebral small-vessel disease in APOE4 carriers. J Am Heart Assoc2024; 13: e034116.
5.
SibleIJ, Nation DA. and Alzheimer's Disease Neuroimaging Initiative. Visit-to-visit blood pressure variability and CSF Alzheimer disease biomarkers in cognitively unimpaired and mildly impaired older adults. Neurology2022; 98: e2446–e2453.
6.
YooJEShinDWHanK, et al.Blood pressure variability and the risk of dementia. Hypertension2020; 75: 982–990.
7.
de HavenonAAnadaniMPrabhakaranS, et al.Increased blood pressure variability and the risk of probable dementia or mild cognitive impairment: a post hoc analysis of the SPRINT MIND trial. J Am Heart Assoc2021; 10: e022206.
8.
LohmanTSibleIEngstromAC, et al.Beat-to-beat blood pressure variability, hippocampal atrophy, and memory impairment in older adults. Geroscience2025; 47: 993–1003.
9.
LohmanTSibleIJShenasaF, et al.Reliability of beat-to-beat blood pressure variability in older adults. Sci Rep2024; 14: 20197.
10.
GratzIDealESpitzF, et al.Continuous non-invasive finger cuff CareTaker® comparable to invasive intra-arterial pressure in patients undergoing major intra-abdominal surgery. BMC Anesthesiol2017; 17: 48.
11.
KwonYStaffordPLBaruchMC, et al.Tracking of the beat-to-beat blood pressure changes by the caretaker physiological monitor against invasive central aortic measurement. Blood Press Monit2022; 27: 70–76.
12.
BakkarNZEl-YazbiAFZoueinFA, et al.Beat-to-beat blood pressure variability: an early predictor of disease and cardiovascular risk. J Hypertens2021; 39: 830–845.
13.
TianGXiongLLeungH, et al.Beat-to-beat blood pressure variability and heart rate variability in relation to autonomic dysregulation in patients with acute mild-moderate ischemic stroke. J Clin Neurosci2019; 64: 187–193.
14.
TomiyamaH. Vascular function: a key player in hypertension. Hypertens Res2023; 46: 2145–2158.
15.
MenaLJFelixVGMelgarejoJD, et al.24-hour Blood pressure variability assessed by average real variability: a systematic review and meta-analysis. J Am Heart Assoc2017; 6: e006895.
16.
MenaLJMaestreGEHansenTW, et al.How many measurements are needed to estimate blood pressure variability without loss of prognostic information?Am J Hypertens2014; 27: 46–55.
17.
MenaLPintosSQueipoNV, et al.A reliable index for the prognostic significance of blood pressure variability. J Hypertens2005; 23: 505–511.
18.
ZhangHHuWWangY, et al.The relationship between ambulatory arterial stiffness index and left ventricular diastolic dysfunction in HFpEF: a prospective observational study. BMC Cardiovasc Disord2022; 22: 246.
19.
LiYWangJ-GDolanE, et al.Ambulatory arterial stiffness index derived from 24-h ambulatory blood pressure monitoring. Hypertension2006; 47: 359–364.
20.
ZiemanSJMelenovskyVDAK. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol2005; 25: 932–943.
21.
PacholkoAIadecolaC. Hypertension, neurodegeneration, and cognitive decline. Hypertension2024; 81: 991–1007.
22.
SibleIJNationDA. 24-h Blood pressure variability via ambulatory monitoring and risk for probable dementia in the SPRINT trial. J Prev Alzheimers Dis2024; 11: 684–692.
23.
SibleIJNationDAWeinerM, et al.Visit-to-visit blood pressure variability and longitudinal tau accumulation in older adults. Hypertension2022; 79: 629–637.
24.
AsmujeNFMatSGohCH, et al.Increased beat-to-beat blood pressure variability is associated with impaired cognitive function. Am J Hypertens2022; 35: 998–1005.
25.
SibleIJNationDA. Blood pressure variability and cerebral perfusion decline: a post hoc analysis of the SPRINT MIND trial. J Am Heart Assoc2023; 12: e029797.
26.
SetiadiAKorimWSElsaafienK, et al.The role of the blood–brain barrier in hypertension. Exp Physiol2018; 103: 337–342.
27.
MortensenKNSanggaardSMestreH, et al.Impaired glymphatic transport in spontaneously hypertensive rats. J Neurosci2019; 39: 6365–6377.
28.
KikutaJKamagataKTakabayashiK, et al.An investigation of water diffusivity changes along the perivascular space in elderly subjects with hypertension. AJNR Am J Neuroradiol2022; 43: 48–55.
29.
de LeeuwF-EKorfEBarkhofF, et al.White matter lesions are associated with progression of medial temporal lobe atrophy in Alzheimer disease. Stroke2006; 37: 2248–2252.
30.
VisserPJVerheyFRJHofmanPAM, et al.Medial temporal lobe atrophy predicts Alzheimer's disease in patients with minor cognitive impairment. J Neurol Neurosurg Psychiatry2002; 72: 491.
31.
EmraniSArainHADeMarshallC, et al.APOE4 Is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review. Alzheimers Res Ther2020; 12: 141.
32.
de JongLWForsbergLEVidalJS, et al.Different susceptibility of medial temporal lobe and basal ganglia atrophy rates to vascular risk factors. Neurobiol Aging2014; 35: 72–78.
33.
WoodworthDCSheikh-BahaeiNScambrayKA, et al.Dementia is associated with medial temporal atrophy even after accounting for neuropathologies. Brain Commun2022; 4: fcac052.
34.
ChatterjeePPedriniSStoopsE, et al.Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease. Transl Psychiatry2021; 11: 27.
35.
PereiraJBJanelidzeSSmithR, et al.Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease. Brain2021; 144: 3505–3516.
36.
KimKYShinKYChangK-A. GFAP As a potential biomarker for Alzheimer’s disease: a systematic review and meta-analysis. Cells2023; 12: 1309.
37.
LewczukPErmannNAndreassonU, et al.Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease. Alzheimers Res Ther2018; 10: 71.
38.
van GennipACESatizabalCLTracyRP, et al.Associations of plasma NfL, GFAP, and t-tau with cerebral small vessel disease and incident dementia: longitudinal data of the AGES-Reykjavik study. Geroscience2024; 46: 505–516.
39.
JungYDamoiseauxJS. The potential of blood neurofilament light as a marker of neurodegeneration for Alzheimer's disease. Brain2024; 147: 12–25.
40.
SaidMAEppingaRNLipsicE, et al.Relationship of arterial stiffness index and pulse pressure with cardiovascular disease and mortality. J Am Heart Assoc2018; 7: e007621.
41.
ZhangSMaoHJSunB, et al.The relationship between AASI and arterial atherosclerosis in ESRD patients. Ren Fail2015; 37: 22–28.
42.
PennyWFristonKAshburnerJ, et al.Statistical parametric mapping: the analysis of functional brain images. New York: Academic Press, 2007.
43.
GaserCDahnkeRThompsonPM, et al.CAT: a computational anatomy toolbox for the analysis of structural MRI data. Gigascience2024; 13: giae049.
44.
Ferrari-SouzaJPBrumWSHauschildLA, et al.Vascular risk burden is a key player in the early progression of Alzheimer’s disease. Neurobiol Aging2024; 136: 88–98.
45.
NationDASweeneyMDMontagneA, et al.Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med2019; 25: 270–276.
46.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: Foundation for Statistical Computing, 2022.
47.
HayesAF.Introduction to mediation, moderation, and conditional process analysis: a regression-based approach. New York: Guilford Press, 2013, p.xvii, 507–xvii, 507.
48.
SibleIJNationDA. Blood pressure variability and medial temporal atrophy in apolipoprotein ɛ4 carriers. Brain Imaging Behav2022; 16: 792–801.
49.
SibleIJYewBDuttS, et al.Visit-to-visit blood pressure variability and regional cerebral perfusion decline in older adults. Neurobiol Aging2021; 105: 57–63.
50.
ClaassenDOMcDonellKEDonahueM, et al.Cortical asymmetry in Parkinson's disease: early susceptibility of the left hemisphere. Brain Behav2016; 6: e00573.
51.
HernándezSARKroonAAvan BoxtelMPJ, et al.Is there a side predilection for cerebrovascular disease?Hypertension2003; 42: 56–60.
52.
PortegiesMLPSelwanessMHofmanA, et al.Left-sided strokes are more often recognized than right-sided strokes. Stroke2015; 46: 252–254.
53.
HednaVSBodhitANAnsariS, et al.Hemispheric differences in ischemic stroke: is left-hemisphere stroke more common?J Clin Neurol2013; 9: 97–102.
54.
BraakHBraakE. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol1991; 82: 239–259.
55.
MolinderAZiegelitzDMaierSE, et al.Validity and reliability of the medial temporal lobe atrophy scale in a memory clinic population. BMC Neurol2021; 21: 289.
56.
LaaksoMPPartanenKRiekkinenP, et al.Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia. Neurology1996; 46: 678–681.
57.
TamCWBurtonEJMcKeithIG, et al.Temporal lobe atrophy on MRI in Parkinson disease with dementia: a comparison with Alzheimer disease and dementia with Lewy bodies. Neurology2005; 64: 861–865.
58.
EckerströmCOlssonEBorgaM, et al.Small baseline volume of left hippocampus is associated with subsequent conversion of MCI into dementia: the göteborg MCI study. J Neurol Sci2008; 272: 48–59.
59.
VisserPJScheltensPVerheyFRJ, et al.Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment. J Neurol1999; 246: 477–485.
60.
DevanandDPPradhabanGLiuX, et al.Hippocampal and entorhinal atrophy in mild cognitive impairment. Neurology2007; 68: 828–836.
61.
KorfESCWahlundL-OVisserPJ, et al.Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology2004; 63: 94–100.
